Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).